KIR genotype distribution among patients with multiplemyeloma: Higher prevalence of KIR 2DS4 and KIR 2DS5 genes

被引:21
作者
Hoteit, R. [1 ]
Bazarbachi, A. [2 ]
Antar, A. [2 ]
Salem, Z. [2 ]
Shammaa, D. [1 ]
Mahfouz, R. [1 ]
机构
[1] Amer Univ Beirut, Med Ctr, Dept Pathol & Lab Med, POB 11-0236, Beirut 11072020, Lebanon
[2] Amer Univ Beirut, Med Ctr, Dept Internal Med, Beirut 11072020, Lebanon
关键词
Myeloma; KIR; Genotype; Lebanon;
D O I
10.1016/j.mgene.2014.09.008
中图分类号
Q3 [遗传学];
学科分类号
071007 ; 090102 ;
摘要
Introduction: Natural killer (NK) cells possess an antitumor activity against multiple myeloma cells proven by the susceptibility of plasmocytes to NK lysis. In the early stage of MM, the killing of MM cells is mediated by natural cytotoxicity receptors (NRC) and NKG2Ddependent pathway, while in the late stage, NK cells lose their killing potential against MM cells due to the high expression of HLA class I molecules on MM cells. Aim: The aim of this paper is to study KIR expression of NK cells in MM patients and in healthy controls, to check for any association between KIR genotypes and MM. Methods: KIR genotype was analyzed in 120 healthy Lebanese individuals and 34 MM patients using the KIR Genotyping SSP kit. Results: KIR 2DS4* 001/ 002 and KIR 2DS5 were found to be significantly more prevalent among MM patients as compared to controls. For MM patients, the AA, AB, and BB genotype frequencies were, respectively, 38.23%, 47.06% and 14.71% with an A: B ratio of 1.62: 1. As for the healthy controls, the AA, AB, and BB genotype frequencies were, respectively, 39.17%, 50%, and 10.83% with an A: B ratio of 1.80: 1. Conclusion: The interesting observation of the significant presence of KIR2DS4 and KIR2DS5 genes more among multiple myeloma patients than controls is worth further clinical, translational as well as survival research studies in these cases. (C) 2014 The Authors. Published by Elsevier B.V.
引用
收藏
页码:730 / 736
页数:7
相关论文
共 12 条
[1]   HLA/KIR Restraint of HIV: Surviving the Fittest [J].
Bashirova, Arman A. ;
Thomas, Rasmi ;
Carrington, Mary .
ANNUAL REVIEW OF IMMUNOLOGY, VOL 29, 2011, 29 :295-317
[2]   Natural killer cells, killer immunoglobulin-like receptors and human leucocyte antigen class I in disease [J].
Boyton, R. J. ;
Altmann, D. M. .
CLINICAL AND EXPERIMENTAL IMMUNOLOGY, 2007, 149 (01) :1-8
[3]   Human natural killer cells [J].
Caligiuri, Michael A. .
BLOOD, 2008, 112 (03) :461-469
[4]   HLA class I, NKG2D, and natural cytotoxicity receptors regulate multiple myeloma cell recognition by natural killer cells [J].
Carbone, E ;
Neri, P ;
Mesuraca, M ;
Fulciniti, MT ;
Otsuki, T ;
Pende, D ;
Groh, V ;
Spies, T ;
Pollio, G ;
Cosman, D ;
Catalano, L ;
Tassone, P ;
Rotoli, B ;
Venuta, S .
BLOOD, 2005, 105 (01) :251-258
[5]   Thalidomide and immunomodulatory derivatives augment natural killer cell cytotoxicity in multiple myeloma [J].
Davies, FE ;
Raje, N ;
Hideshima, T ;
Lentzsch, S ;
Young, G ;
Tai, YT ;
Lin, B ;
Podar, K ;
Gupta, D ;
Chauhan, D ;
Treon, SP ;
Richardson, PG ;
Schlossman, RL ;
Morgan, GJ ;
Muller, GW ;
Stirling, DI ;
Anderson, KC .
BLOOD, 2001, 98 (01) :210-216
[6]   Impaired activating receptor expression pattern in natural killer cells from patients with multiple myeloma [J].
Fauriat, C ;
Mallet, F ;
Olive, D ;
Costello, RT .
LEUKEMIA, 2006, 20 (04) :732-733
[7]   Anti-myeloma activity of natural killer lymphocytes [J].
Frohn, C ;
Höppner, M ;
Schlenke, P ;
Kirchner, H ;
Koritke, P ;
Luhm, J .
BRITISH JOURNAL OF HAEMATOLOGY, 2002, 119 (03) :660-664
[8]   Some human KIR haplotypes contain two KIR2DL5 genes:: KIR2DL5A and KIR2DL5B [J].
Gómez-Lozano, N ;
Gardiner, CM ;
Parham, P ;
Vilches, C .
IMMUNOGENETICS, 2002, 54 (05) :314-319
[9]   Molecular mechanisms whereby immunomodulatory drugs activate natural killer cells: clinical application [J].
Hayashi, T ;
Hideshima, T ;
Akiyama, M ;
Podar, K ;
Yasui, H ;
Raje, N ;
Kumar, S ;
Chauhan, D ;
Treon, SP ;
Richardson, P ;
Anderson, KC .
BRITISH JOURNAL OF HAEMATOLOGY, 2005, 128 (02) :192-203
[10]   Clinical stage-depending decrease of NK cell activity in multiple myeloma patients [J].
Jurisic, Vladimir ;
Srdic, Tatjana ;
Konjevic, Gordana ;
Markovic, Olivera ;
Colovic, Milica .
MEDICAL ONCOLOGY, 2007, 24 (03) :312-317